Immuno-Oncology Panel Session

Kineticos recently tapped 3 industry veterans and Oncology experts to participate in a panel to discuss where we are today in terms of the Immuno-Oncology treatment landscape and what the future holds.  In this fourth and final installment of the series, the panelist talk through the theory and practice of using AI in drug development.

Panel Members

  • Chris Heery – Chief Medical Officer, Bavarian Nordic
  • Jeff Kmetz – Former Chief Business Officer, Pulse Biosciences
  • Alex Dusek – Vice President of Commercial Strategy, Erytech

Click here for a condensed and edited version of Part 4.

Immuno-Oncology Series